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Abstract: Understanding the molecular mechanisms involving the initiation, progression, and metastasis of ovarian 
cancer is important for the prevention, detection, and treatment of ovarian cancer. In this study, two ovarian cancer 
cell lines, HO-8910 and its derivative HO-8910PM with highly metastatic potential, were applied to comparative 
genomic hybridization (CGH) analysis. We found 14 chromosome fragments with different copy numbers between 
the two cell lines, one (2q36.1-37.3) of which was confirmed to be one-copy loss in HO-8910PM by fluorescent in 
situ hybridization (FISH). Using the microarray data on gene expression profiles from these cell lines, 6 significantly 
expression-decreased genes located on 2q36.1-37.3 in HO-8910PM were identified. Of the 6 genes, ARL4C was 
identified as a novel ovarian cancer-related gene using integrated molecular and genomic analyses. ARL4C mRNA 
expression was validated by quantitative PCR to be markedly decreased in HO-8910PM cells, compared to that 
in HO-8910. Both overexpression and knockdown of ARL4C demonstrated that low ARL4C expression promotes 
the migration but not influences proliferation capability of ovarian cancer cells in vitro, indicating its specific role 
in ovarian cancer progression. Furthermore, ovarian cancer patients with medium and high expression of ARL4C 
mRNA had a favorable prognosis compared to those with low expression, suggesting the ARL4C could be a potential 
predictor for ovarian cancer prognosis.
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Introduction 
Ovarian cancer is the fourth leading cause of 
cancer mortality among women in Western 
societies [1]. There were 22,280 new cases of 
ovarian cancer diagnosed in the US and 15,500 
deaths in 2012 [2]. Due to the lack of specific 
symptoms and signs at early stage of the dis-
ease onset, most of the patients with ovarian 
cancer are diagnosed late; about 75% of pa- 
tients have extensive metastasis in the abdom-
inal cavity when diagnosed. Patients with ovar-
ian cancer have less than 50% chance of 5-year 
survival. A majority of patients die of disease 
recurrence or metastasis, even though the 
tumors are sensitive to initial treatment and the 
patients are cleared from the primary malig-
nancy [3, 4]. Direct spread and peritoneal seed-
ing (exfoliation of cells into the peritoneal cavi-
ty) are the main routes of ovarian cancer metas-
tasis. Tumor cells directly invade adjacent or- 
gans, and widely seed on the peritoneal and 
omental surfaces, causing massive ascites. 
Hematogenous metastasis occurs at advanced 
stage, and the most common sites are liver, 
lung, pleura, kidney, bone, adrenal gland and 
spleen [5].
Recent studies have revealed many novel 
metastasis-related genes in ovarian cancer. 
Scaffolding adaptor protein Gab2, over-ex- 
pressed in ovarian cancer cells, inhibits E-ca- 
dherin expression and promotes characteris-
tics of EMT in ovarian cancer cells by activation 
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of the PI3K-Zeb1 pathway [6]. Mucin 4 (MUC4) 
induces EMT through upregulation of N-cad- 
herin and promotes metastasis of ovarian can-
cer cells [7]. Lysophosphatidic acid (LPA)-
induced Rac activation is a prerequisite for 
ovarian cancer metastasis, and the integrity of 
SOS1/EPS8/ABI1 tri-complex is a determinant 
of ovarian cancer metastasis [8]. In addition, 
the latest study indicates that adipocytes, a 
major component of tumor microenvironment, 
provide fatty acids as energy for rapid growth of 
tumor cells and promote migration and inva-
sion of ovarian cancer cells to the omentum 
through their secreted adipokines, such as in- 
terleukin-8 (IL-8). Fatty acid binding protein 
(FABP4), a transport coordinator of lipids be- 
tween adipocytes and tumor cells, plays a key 
role in ovarian cancer metastasis [9]. Although 
recent studies have revealed several molecular 
mechanisms involved in the metastasis of ovar-
ian cancer, much remains unknown regarding 
how cancerous cells initiate metastasis and 
colonize at a secondary organ. So, more stud-
ies are needed to further explore the mecha-
nisms of ovarian cancer metastasis.
Genetic alterations are the key events in the ini-
tiation and promotion of many malignant tu- 
mors, including ovarian cancer [10, 11]. Usually, 
cancer-related genetic changes can result in 
activation of oncogenes and inactivation of 
tumor suppressor genes, which are responsible 
for tumor metastasis, drug resistance and 
other biological behaviors of malignant tumor 
cells [12, 13]. Comparative genomic hybridiza-
tion (CGH) is an effective method to identify 
large changes in genomic DNA, such as copy 
number variation, and has been shown to be 
useful in identification of novel oncogenes and 
tumor suppressor genes with accurate chromo-
somal location [13]. In the present study, using 
a CGH chip combined with gene expression pro-
filing, we compared ovarian cancer cells with 
high (HO-8910PM) and low (HO-8910) meta-
static potential, and identified ARL4C, located 
on chromosome 2q37.1, to be down-regulated 
in HO-8910PM cells, as compared with HO- 
8910. To further explore the biological actions 
of ARL4C in ovarian cancer, we investigated the 
effects of ARL4C over- and down-expression 
mediated by lentiviral vectors on colony forma-
tion, cell proliferation and motility of ovarian 
cancer cells. In addition, we analyzed ARL4C 
mRNA expression in association with clinico-
pathological features of ovarian cancer and 
patient survival.
Materials and methods
Cell lines and culture 
Ovarian cancer cell lines, HO-8910 and HO- 
8910PM, were established from our previous 
studies [14, 15]; SKOV3, OVCAR3 and Es-2 
cells were purchased from American Type 
Culture Collection (Manassas, VA). A2780 cells 
were obtained from Sigma-Aldrich Company (St 
Louis, MO). COC1 cells were bought from 3D 
High Throughput Screening Co., Ltd (Shanghai, 
China). OVCAR8 cells were a gift from Dr. Qi- 
aojun He (Zhejiang University, Zhejiang, China). 
SKOV3 cells were cultured in DMEM medium, 
and HO-8910, HO-8910PM, A2780, SKOV3, 
OVCAR3, OVCAR8, COC1, and Es-2 cells were 
cultured in RPMI-1640 medium containing 10% 
newborn bovine serum, supplemented with 
100 U/ml penicillin and 125 µg/ml streptomy-
cin. All cell cultures were incubated at 37°C 
with 5% CO2. 
DNA isolation and CGH analysis  
DNA was isolated from cells using the standard 
phenol/chloroform method. The Affymetrix 
GeneChip® Mapping Assay, in conjunction with 
the GeneChip Human Mapping 10K Array 2.0 
(Affymetrix Inc., Santa Clara, CA), were used to 
analyze chromosomal regions with different 
copy numbers between HO-8910 and HO- 
8910PM cell lines. The analysis was performed 
according to the assay manual. The protocol 
started with 250 ng of genomic DNA which was 
first digested with 20,000 U/ml Xba I restriction 
enzyme (New England Biolab Ltd, HERTS, UK) 
and then ligated with a special sequence using 
T4 DNA Ligase (New England Biolab Ltd, HERTS, 
UK). Following the ligation, PCR procedure was 
performed to amplify the ligated DNA, and then 
followed by fragmentation and end-labeling of 
PCR products. The labeled DNA was hybridized 
to the GeneChip array. After hybridization, the 
array was washed, stained, scanned and read. 
Chromosome Copy Number Analysis Tool (CN- 
AT) software 4.0 (Affymetrix Inc., Santa Clara, 
CA) was used to analyze the chromosomal copy 
number changes. Data were normalized with 
quartile normalization and log2 ratio; replicat-
ed data points that exceeded a standard devia-
tion of 0.075 were excluded. Paired copy num-
ber (CN) analysis with Hidden Markov Model 
(HMM) parameters was applied, and DNA from 
HO-8910 cells was used as reference.
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Fluorescent in situ hybridization (FISH) 
Chromosomes from HO-8910 and HO-8910PM 
ovarian cancer cells were prepared with colchi-
cine at a final concentration of 0.07 μg/ml. Four 
biotin labeled bacterial artificial chromosome 
(BAC) clone probes separately mapping onto 
2q35, and 2q37.1 were purchased from Si- 
noGenoMax Research Center Co., Ltd (Beijing, 
China). These probes were used to separately 
hybridize to the preparations of fixed cell nuclei 
and metaphases previously dehydrated and 
denatured for 2 minutes in 70% formamide at 
72°C. The probe was denatured for 5 minutes 
at 72°C, and the hybridization was performed 
at 37°C overnight. After washing in 0.4 × SSC 
at 72°C for 2 minutes and 2 × SSC at room tem- 
perature for 30 seconds, avidin-FITC was added 
to enlarge the signal of hybridization for 40 min-
utes at 37°C, followed by antiavidin incubation 
for 40 minutes at 37°C. After washing in 2 × 
SSC at room temperature, PI was added on the 
slide. Hybridization signal was observed under 
a fluorescence microscope (Nikon, Tokyo, Ja- 
pan) with FITC filter and photographed at a ma- 
gnification of 400 ×. More than 30 metaphase 
and interphase cells were analyzed for each 
sample. Chromosomes from normal peripheral 
blood lymphocytes were used as control. Bright 
and round green dots located on the sister 
chromatid were determined as real signals.
Quantitative reverse-transcriptase polymerase 
chain reaction (qRT-PCR) 
RNeasy Mini kits (QIAGEN Inc., Valencia, CA) 
were used to extract total RNA from cells and 
tissue. RNA (500 ng) was reverse transcribed 
to cDNA using the SuperScript First-Strand Sy- 
nthesis System for RT-PCR (Invitrogen Corp., 
Carlsbad, CA). Quantitative PCR was performed 
to determine the expression of ARL4C mRNA in 
each tumor sample, using GAPDH as an endog-
enous control for calibration. The primer se- 
quences were designed using an online tool 
(http://www.idtdna.com), and the primers were 
ordered from Invitrogen Corp (Shanghai, China). 
The primer sequences were: TGG AAG GCT CAG 
TTG TCG GAA AGA (ARL4C forward), TAC ACA 
TGG ACA GGG TCC AAA CCA (ARL4C reverse); 
GAA GGT GAA GGT CGG AGT C (GAPDH forward), 
and GAA GAT GGT GAT GGG ATT TC (GAPDH 
reverse). ABI 7500 real-time PCR system (Ap- 
plied Biosystems Inc., Foster City, CA) was used 
for qPCR reaction. The PCR solution (25 µl) con-
tained 5 ng/µl cDNA, 12.5 µl Power SYBR 
Green PCR Master Mix (Bioer Technology Inc., 
Hangzhou, China) and a pair of primers at a 
final concentration of 0.1 µM for ARL4C and 
GAPDH. Dissociation curve analysis was per-
formed after PCR amplification to confirm the 
size of PCR products. All tumor samples were 
analyzed in duplicate along with negative con-
trols. Real-time PCR results were recorded as 
Ct values (threshold cycle). To adjust for the 
total amount of cDNA used for analysis in each 
sample, a ΔCt was calculated based on the dif-
ference in Ct values between the target ARL4C 
and housekeeping gene GAPDH. ΔCt was fur-
ther converted to an expression index (EI) 
based on the formula 2(-ΔCt). 
Western blot analysis
Cultured cells were harvested with 0.02% EDTA 
and 0.025% trypsin, rinsed three times in phos-
phate-buffered saline (PBS), and lysed in 300 
μl SDS-lysis buffer supplemented with a cock-
tail of inhibitors for protease. Protein concen-
tration in cell lysate was measured with the 
Bradford calorimetric assay (Bio-Rad, Rich- 
mond, California). Thirty μg of total protein from 
each sample were electrophoresed on an 8% 
SDS-PAGE gel, and the proteins on the gel were 
transferred onto a PVDF membrane (Millipore, 
MA). The membranes were blocked with TBST 
containing 5% non-fat milk for one hour at room 
temperature, and then incubated with anti-
ARL4C antibody (Atlas Antibodies company, 
Stockholm, Sweden) for one hour at room tem-
perature, following by further incubation with a 
HRP-conjugated secondary antibody and detec-
tion with ECL regent (Millipore, MA). GAPDH 
(Sigma, St Louis, MO) was used as a loading 
control. 
ARL4C knockdown and overexpression 
The lentiviral vector with shRNA for ARL4C, 
pLenti-U6- tdTomato -puromycin -shRNA-ARL4C 
vector, which contains a red fluorescent protein 
(tdTomato) marker for cell tracking, and the len-
tiviral vectors carrying ARL4C, pLenti-EF1α-
copGFP-puromycin-ARL4C cDNA expression 
lentiviral Vector, which contains a green fluo-
rescent protein (copGFP) marker, were pur-
chased from 3D High Throughput Screening 
Co., Ltd (Shanghai, China). Empty lentiviral vec-
tor was used as control. The lentiviral vectors 
and pHelper plasmids were co-transfected into 
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293T cells. The culture supernatants were col-
lected, concentrated, and used as a virus 
stock. Ovarian cancer cells at 40%-50% conflu-
ence were infected with ARL4C-shRNA or 
ARL4C-overexpression lentivirus or control len-
tivirus. 72 hours after infection, the knockdown 
efficiency and the overexpression of ARL4C in 
ovarian cancer cells was validated by western 
blot.
Colony formation assay
A total of 2,000 cells, infected with ARL4C-
overexpression or ARL4C-shRNA lentivirus for 
72 hours, were seeded onto 6-well plates and 
allowed to grow for 10 days in complete culture 
medium which was changed every 2 days. The 
number of cell colonies was counted after 
staining with 5% crystal violet for 15 minutes.
Cell proliferation assay 
Cells were infected with ARL4C-overexpression 
or ARL4C-shRNA lentivirus for 72 hours, and 
then plated in 96-well plates at 5 × 103 cells/
well. After allowing for adherence overnight, cell 
viability was measured at 0, 24, 48, 72 and 96 
hours. Cell viability was determined by MTT 
(3-[4,5-dimethylthiazol -2-yl]-2,5 diphenyl tetra-
zolium bromide) reagent (Sigma, St Louis, MO) 
according to the manufacturer’s instructions. 
The procedure also included adding reconsti-
tuted MTT in an amount equal to 10% of the 
culture medium volume and returning to incu-
bator for 2 hours. After that, medium was 
moved, and MTT formazan was resolved in 100 
ul acidic isopropanol. Absorbance was mea-
sured at wavelength 570 nm. Experiments were 
performed in triplicate, and 3 different experi-
ments were performed for each experimental 
condition.
Transwell migration and invasion assay 
Cancer cell migration was performed toward a 
serum gradient in a Boyden chamber (Millipore, 
MA) consisting of a cell culture insert (6.4 mm 
diameter, 8-μm pore polyethylene terephthal-
ate membrane) seated in each well of a 24-well 
plate. Briefly, cells were infected with ARL4C- 
overexpression or ARL4C-shRNA lentivirus for 
72 hours, and then seeded into the upper ch- 
amber at a number of 105 cells in 100 μl serum-
free medium, while 500 μl medium with 10% 
FBS were added to the lower chamber. Tran- 
swells were incubated for 24 hours at 37°C. 
Cells inside of the transwell inserts were re- 
moved with a cotton swab, and cells on the 
underside of the insert filter were fixed and 
stained. Photographs of four random fields 
were taken, and the cells were counted to cal-
culate the average number of migrated cells. 
Ovarian cancer patients and tumor samples
The study analyzed ARL4C mRNA expression in 
fresh frozen tumor samples of 212 patients 
who underwent surgery for primary ovarian 
Table 1. Chromosome segments with different copy number between HO-8910PM and HO-8910
Chromosome Region
Physical Location 
Size (kb) Copy number status*  (HO-8910PM/HO-8910)Start End
1 p21.1 1.05E+08 1.05E+08 80.186 1
1 q21.2 1.47E+08 1.48E+08 99.504 1
2 q35 2.16E+08 2.21E+08 4771.496 3
2 q36.1-37.3 2.22E+08 2.41E+08 19020.56 1
3 p12.2 83182109 83190195 8.087 1
5 p13.3-13.2 30867734 35879721 5011.988 1
5 q21.3-31.2 1.07E+08 1.37E+08 29641.55 1
6 p12.3-11.2 49274737 57101087 7826.351 1
9 q34.12-34.13 1.34E+08 1.35E+08 944.913 1
11 q12.1 55923662 56007810 84.149 3
11 p14.3 25338244 25636591 298.348 1
15 p13.3 32790601 32880524 89.924 1
20 q13.2-13.31 53751202 55769147 2017.946 1
X p21.3 28488483 28488590 0.108 1
*Copy number states: “1” means one copy loss; “3” means one copy gain. HO-8910 cells as a reference.
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cancer in the Department of Gynecology and 
Obstetrics at University of Turin in Italy. The 
specimens were collected for a clinical study of 
epithelial ovarian cancer that was approved by 
the university’s ethical review committee. The 
average age of patients at surgery was 57.6 
years (SD, 11.5; range, 26-82). Follow-up infor-
mation was available for 203 patients who 
were followed from surgery to June 2001. The 
overall follow-up time ranged from 0.6 to 114 
months, and the median was 31 months. The 
median disease progression-free survival was 
20.6 months. Disease stage was classified 
according to the criteria of FIGO (the In- 
ternational Federation of Gynecologists and 
Obstetricians) [16]. Of the 211 patients with 
information on disease stage, 51 (24.2%) were 
diagnosed with stage I disease, 12 (5.7%) were 
stage II, 133 (63.0%) were stage III, and 15 
(7.1%) were stage IV. Histological type deter-
mined following the World Health Organization 
(WHO) criteria [17] included serous, endometri-
oid, mucinous, clear cell, and other epithelial 
tumors. For data analysis, tumor histotype were 
grouped into non-serous (59.9%, n=127) and 
serous (40.1%, n=85). Of the 211 patients with 
information on tumor grade, most patients 
(65.4%, n=138) had grade 3 tumors (poorly dif-
ferentiated); few had grade 1 or 2 (34.6%, 
n=73). Most of the patients received standard 
postoperative chemotherapy after cytoreduc-
tion surgery. Of the patients treated, 90 (42.4%) 
had no residual tumor, but 116 (54.7%) had 
residual tumors. Six patients lacked the infor-
mation on residual tumor. Patient’s response to 
chemotherapy was evaluated one month after 
the last cycle of treatment through clinical ex- 
amination, imaging, and serum CA125. For 
measurable disease, treatment response was 
assessed following the WHO criteria [17]. For 
non-measurable disease, progression was de- 
fined by CA125, doubling from the upper limit of 
normal range [18]. For data analysis, PR (par-
tial response), SD (stable disease), and PD (pro-
gressive disease) were grouped together as 
poor responders to compare with CR (comple- 
te response). Of the 212 patients, 68.7% (n= 
145) had complete response to treatment, and 
25.9% (n=55) had poor response. Twelve pa- 
tients (5.4%) had no information on treatment 
response.
Statistical analysis
Data from in vitro experiments were expressed 
as means and standard deviations (SD) for 3 
independent experiments using three different 
preparations. The differences between means 
Figure 1. Detection of differentiated chromosome 
fragments in HO-8910 and HO-8910PM by FISH. 
Chromosomes in HO-8910 and HO-8910PM ovar-
ian cancer cells were prepared by colchicine. Biotin 
labeled BAC clones probes were used to separately 
hybridize preparations of fixed cell nuclei and meta-
phases. Hybridization signal was observed under a 
fluorescence microscope with FITC filter and photo-
graphed at a magnification of 400 ×. More than 30 
metaphases and interphase cells were analyzed for 
each sample. Normal peripheral blood lymphocyte 
chromosome was as a control. Bright and round 
green dots located on the sister chromatid were de-
termined as real signal. Chromosome hybridization 
signals for 2p37.1, two chromosome hybridization 
signals for 2p37.1 in HO-8910, and only one chromo-
some hybridization signal was shown in HO-8910PM 
cells. 
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were compared using the Student’s t-test. For 
patient data, ARL4C mRNA expression was 
analyzed both as a continuous and categorical 
variable. For categorical analysis, the expres-
sion data were grouped into low, middle and 
high categories based on tertile distributions. 
Associations between ARL4C expression and 
clinical variables were analyzed using the Chi-
square test. Survival analysis was performed 
for progression-free and overall survival using 
a hemizygous deletion of chromosome 2p37.1 
in the latter cells (Figure 1). 
Analysis of gene expression in ovarian cancer 
cells 
Based on the results of our CGH and FISH anal-
yses, we focused our genetic evaluation on 
chromosome 2q36.1-37.3. Using our previous 
gene-expression profiling data [19], we found 
that 6 genes located on chromosome 2q36.1-
Table 2. Down-regulated genes located in chromosome 2q36.1-
37.3 in HO-8910PM compared with those in HO-8910
Chromosome 
Location Locus Gene
Signal Log Ratio  
(HO-8910PM vs H08910)
chr2q37.1 NM_005737 ARL4C -3.8
chr2q37.3 NM_023083.3 CAPN10 -3.8
chr2qter NM_001463.3 FRZB -3.4
chr2q37 NM_001172416.1 KCNJ13 -3.1
chr2q37.1 NM_001080391.1 SP100 -2.9
chr2q37.3 NM_001244008.1 KIF1A -2.7
Figure 2. The deletion of ARL4C in various cancers (COSMIC data). A. CNV 
of five genes in ovarian cancer tissues from COSMIC data. The proportion 
of amplification (Amp) or deletion (Del) was relative to the total number of 
Amp and Del in ovarian cancer tissues. B. ARL4C deletion or expression-
decrease was reported in various cancers by cBioPortal data.
the Cox proportional hazards 
regression and Kaplan-Meier cu- 
rves. All p-values were two-sid-
ed, and a probability of 0.05 or 
smaller was considered statisti-
cal significance. SPSS version 
11.0 (SPSS Inc., Chicago, IL) was 
used for data analysis.
Results
Comparison of chromosome 
fragments between cell lines 
HO-8910PM had 14 chromo-
some fragments with different 
copy numbers from HO-8910 
cell line, mainly in chromosomes 
1, 2, 3, 5, 6, 9, 11, 15, 20 and X. 
85.7% (12/14) of the fragments 
lost one copy, and 14.3% (2/14) 
of the fragments gained one 
(Table 1). The shortest fragment 
(0.108 kb) was located on chro-
mosome X p21.3, and the lon-
gest one (29641.546 kb) was on 
chromosome 5q21.3-31.2. Ch- 
romosome 2q36.1-37.3 was the 
second longest fragment (190- 
20.56 kb) which had only one 
copy in HO-8910PM cells.
To validate the results of CGH 
analysis, we performed FISH as- 
say on these two cell lines using 
one commercially available bio-
tin-labeled BAC probes to detect 
the copy number change of chro-
mosome fragments in 2q37.1. 
Consistent with the CGH results, 
two chromosomal hybridization 
signals were found for 2p37.1 in 
HO-8910, but only one was sh- 
own in HO-8910PM, suggesting 
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37.3 were down-regulated (Signal Log Ratio 
[SLR] ≤ -2.7) in HO-8910PM, compared to 
HO-8910. ARL4C, which encodes ADP-ribo- 
sylation factor-like 4C, was the most obviously 
differentiated gene with 3.8-fold decreased 
expression in HO-8910PM than in HO-8910 
(Table 2). The other five genes, CAPN10, FRZB, 
KCN13, SP100 and KIF1A, were found to be 
gain or loss on copy number in ovarian cancer 
tissues according to the COSMIC CNV data 
(Figure 2A), whereas ARL4C was annotated to 
be rather deleted or decreased in mRNA ex- 
pression than amplified in several tumors, such 
as glioma, prostate cancer, and cervical cancer 
by cBioPortal data (Figure 2B), which is in line 
with our observation that ARL4C deletion in 
ovarian cancer cell line might have more meta-
static potential. Hence, we concentrated on the 
correlation between ARL4C CNV/expression 
with the metastatic potential in the subsequent 
studies. 
And then, ARL4C protein and mRNA expression 
was analyzed in HO-8910, HO-8910PM, A2780, 
OVCAR3, SKOV3, OVCAR8, COC1, and Es-2 
cells by Western blot and qPCR. ARL4C protein 
expression was either low or depleted in HO- 
8910, HO-8910PM, A2780 and OVCAR3, com-
pared to that in SKOV3, OVCAR8, COC1 and 
Es-2 (Figure 3A). The protein level of ARL4C 
was too low to be investigated in HO-8910 by 
Western blot, however, the mRNA expression of 
ARL4C in HO-8910PM was significantly de- 
creased by 30% (p=0.004), compared to that in 
HO-8910 (Figure 3B). This result is consistent 
with our CGH and FISH data.
ARL4C overexpression or knockdown influ-
ences migration but not proliferation capability 
of ovarian cancer cells in vitro
To evaluate the effects of ARL4C on the behav-
iors of ovarian cancer cells, we performed lenti-
viral vector-mediated overexpression of ARL4C 
in ARL4C-low expressed HO-8910PM and OV- 
CAR3 cell lines and knockdown of ARL4C in 
ARL4C-highly expressed SKOV3 cell line. As 
shown in Figure 4A-C, 72 hours after transfec-
tion, 80% cells were observed with fluores-
cence (expression vector in green and shRNA 
vector in red). ARL4C overexpression and kno- 
ckdown were validated by Western blot, respec-
tively (the lower panel of Figure 4A-C). For 
ARL4C knockdown in SKOV3 cells, two shRNA 
species were applied to rule out the possibility 
of off-target effects in RNAi experiments [20]. 
The results showed that the ARL4C was totally 
silenced on protein level in SKOV3 cells follow-
ing the treatment of the two shRNA species, 
indicating that the knockdown effects were not 
caused by off-target effects. 
And then, the effect of ARL4C expression on 
ovarian cancer cell growth was investigated by 
Figure 3. ARL4C protein and mRNA expression in ovarian cancer cell lines. A. ARL4C protein levels examined by 
western blot. GAPDH was applied for input control. B. ARL4C mRNA expression examined by qPCR. ARL4C mRNA 
expression was calculated relative to that in HO-8910 cell line.
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colony formation and MTS assay. As shown in 
Figure 5, neither ARL4C overexpression nor 
ARL4C lower expression had obvious effects on 
colony formation (Figure 5A, 5B) and prolifera-
tion (Figure 5C) of ovarian cancer cells.
Subsequently, transwell migration experiments 
showed that the migration capability of ARL4C- 
overexpressed HO-8910-PM and OVCAR3 cells 
were decreased to 20% or so of the control 
cells, (Figure 6A, 6B, p < 0.001 and p < 0.01 for 
HO-8910-PM and OVCAR3 cells, respectively). 
Conversely, ARL4C knockdown increased the 
migration ability of SKOV3 cells by more than 
70% when compared to the control cell (Figure 
6C, p < 0.001 for the two shARL4C species). 
These results suggested that ARL4C should 
suppress the migration of ovarian cancer cells 
in vitro. 
Associations of ARL4C mRNA expression with 
disease characteristics and patient survival
We then examined possibility that the ARL4C 
expression is associated with the clinical out-
come of patients with ovarian tumor. ARL4C 
expression was detected in the tumor samples, 
and the expression ranged from < 0.004 to 
3.930 EI with a median of 0.013 EI. No signifi-
cant associations were found between ARL4C 
expression and disease stage, tumor grade, 
histological type, or residual tumor size. 
Figure 4. Overexpression and knockdown of 
ARL4C in ovarian cancer cells by lentiviral 
vectors-mediated transfection. Infected cells 
with fluorescent by ARL4C overexpression or 
ARL4C shRNA lentivirus for 72 hours in ovari-
an cells were shown, empty vector lentivirus as 
a control. ARL4C protein levels were validated 
by Western blot. β-actin was applied for input 
control. A. ARL4C overexpression in HO-8910-
PM cells. B. ARL4C overexpression in OVCAR3 
cells. C. ARL4C knowdown in SKOV3 cells. 
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However, there was a trend that ARL4C expres-
sion was lower in patients with residual tumors 
or who had poor treatment response than in 
those without residual tumors or who had good 
treatment response (0.009 versus 0.019, 
p=0.095, and 0.008 versus 0.014, p=0.055), 
respectively (Table 3).
ARL4C expression was not associated with dis-
ease progression-free survival, but there was a 
significant association between ARL4C and 
overall survival of ovarian cancer patients. 
Patients having medium or high ARL4C expres-
sion had better survival time than those with 
low expression. The 5-year overall survival rate 
in patients with low expression of ARL4C was 
35%; while for patients with medium and high 
expression of ARL4C, the rate was 52%. The 
medium survival times for these two groups 
were 38.4 and 64.3 months, respectively 
(Figure 7). Cox regression analysis showed that 
high ARL4C expression was associated with 
lower risk of death and the association was 
independent of other prognostic factors for 
ovarian cancer. Patients with medium or high 
levels of ARL4C mRNA had hazard ratios of 
Figure 5. ARL4C has no effect on ovarian cancer cells growth. A. Colony formation assay. Ovarian cancer cells were 
infected by empty vector lentivirus (control), ARL4C overexpression or ARL4C shRNA lentivirus, and then allowed to 
grow for 10 days and stained with crystal violet and photographed. Magnification: 200×. B. Histogram of colony for-
mation experiments. C. Growth curve for ovarian cancer cells infected with empty vector lentivirus (control), ARL4C 
overexpression or ARL4C shRNA lentivirus. 72 hours after infection, cells were seeded into 96-well plate to observe 
the cell viability. Cell viability was determined at 0, 24, 48, 72, and 96 hours by MTT assay. Error bars indicated SD 
from measurement of triplicate plates.
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0.59 (95% CI: 0.39-0.91; P=0.017), after adju- 
sting for age at surgery, disease stage, tu- 
mor grade, histological type and residual tumor 
size (Table 4).
Discussion 
In the present study, we demonstrated that the 
genomic profile of a highly metastatic cell line 
HO-8910PM was different from that of its 
parental cell line HO-8910, with the former dis-
playing fewer copy numbers in several chromo-
some fragments. Using FISH, we further con-
firmed that HO-8910PM had one copy number 
less than HO-8910 in chromosome fragment 
2q36.1-37.3. 
And then, comparison of gene expression pro-
files between the two cell lines indicated that 6 
genes located on chromosome 2q36.1-37.3 
had lower expression in HO-8910PM than in 
HO-8910. ARL4C was the most obviously dif-
ferentiated gene with 3.8-fold decreased ex- 
pression in HO-8910PM than in HO-8910. 
Moreover, the other 5 genes were reported to 
be amplified or deleted in ovarian cancer tis-
sues by COSMIC database (Figure 2A), sug-
gesting that these genes might not be suitable 
candidates for further studies. Therefore, 
ARL4C, the only one gene reported to be delet-
ed in various cancers by cBioPortal data (Figure 
2B), was chosen for further functional ex- 
periments.
Figure 6. ARL4C overexpression or knockdown significantly influences ovarian cancer cells migration in vitro. Ovar-
ian cancer cells were infected by empty vector lentivirus (control), ARL4C overexpression or ARL4C shRNA lentivirus. 
72 hours later, infected cells were seeded into the upper chamber. 24 hours later, the migrated cells were stained 
with crystal violet and photographed. Magnification: 200×. Error bars indicated SD from measurement of triplicate 
experiments. **, P<0.01; ***, P<0.001. A. ARL4C overexpression significantly suppressed migration of HO-8910-
PM cells. B. ARL4C overexpression significantly suppressed migration of OVCAR3 cells. C. ARL4C knockdwon signifi-
cantly promoted migration of SKOV3 cells. 
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ADP-ribosylation factor-like 4C (ARL4C), also 
known as ARL7, is a member of the ADP-
ribosylation factor family of GTP-binding pro-
teins [21, 22]. In 1999 Jacobs et al. isolated 
cDNA containing a full-length coding sequence 
of ARL4C from human bladder epithelia. The 
ARL4C protein has 192 amino acids, of which 
71% were in homology with mouse ARL4, 59% 
in homology with human ARL6 and 49% in 
homology with ARF1 [23]. ARL4C is closely simi-
lar to ARL4A and ARL4D, and each has a nucle-
ar localization signal and an unusually high gua-
nine nucleotide exchange rate [23-25]. Early 
studies found that ARL4C has an inherently fast 
Table 3. Association of ARL4C mRNA expression with clinical and pathological characteristics of ovar-
ian cancer
Variable n
ARL4C Expression
Median (5th-95th)a p-valueb
Lowc Middled Highe
p-valuef
n (%) n (%) n (%)
Stage 211
    I-II 63 0.012 (0-1.334) 0.556 19 (30.2) 22 (34.9) 22 (34.9) 0.830
    III-IV 148 0.014 (0-1.346) 51 (34.5) 48 (32.4) 49 (33.1)
Grade 211
    1-2 73 0.012 (0-2.129) 0.769 24 (32.9) 25 (34.2) 24 (32.9) 0.970
    3 138 0.013 (0-0.919) 46 (33.3) 45 (32.6) 47 (34.1)
Histology 212
    Non-Serous 127 0.014 (0-1.366) 0.188 36 (28.3) 45 (35.4) 46 (36.2) 0.209
    Serous 85 0.012 (0-1.208) 34 (40.0) 25 (29.4) 26 (30.6)
Residual Tumor 206
    No Residual 90 0.019 (0-1.465) 0.095 26 (28.9) 30 (33.3) 34 (37.8) 0.345
    Residual 116 0.009 (0-1.348) 44 (37.9) 37 (31.9) 35 (30.2)
Treatment response
    Complete 145 0.014 (0-1.347) 0.055 45 (31.0) 49 (33.8) 51 (35.2) 0.246
    Poor 55 0.008 (0-0.859) 24 (43.6) 15 (27.3) 16 (29.1)
aExpression levels at the 5th and 95th percentiles; bWilcoxon two-sample test with t approximation; cLow: Expression Index (EI) 
<0.004; dMiddle: Expression Index (EI) 0.005-0.047; eHigh: Expression Index (EI) > 0.054-3.930; fp-value from Chi-square test.
Figure 7. Kaplan-Meier curves for overall survival of patients with ovarian cancer according to ARL4C mRNA levels.
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GTP enzyme activity and plays an important 
role in apolipoprotein AI dependent cholesterol 
secretion process [26]. Recent studies found 
that ARL4C interacts with alpha-tubulin and 
modulates intracellular vesicular transport 
[27]. However, there are no reports that ARL4C 
is involved in tumor initiation and progression 
yet. 
We then assessed the protein and mRNA 
expression of ARL4C in 8 ovarian cancer cell 
lines, including HO-8910 and HO-8910PM. 
Unfortunately, the protein level of ARL4C in 
HO-8910 was too low to be investigated by 
western blot, hence the protein levels between 
HO-8910 and HO-8910PM could not be com-
pared. However, ARL4C mRNA expression was 
significantly decreased in HO-8910PM com-
pared to that in HO-8910, supporting that 
ARL4C deletion in HO-8910PM leads to func-
tional impairment on mRNA, and perhaps pro-
tein levels.
Subsequently, our in vitro functional experi-
ments demonstrated that ARL4C negatively 
regulate motility of ovarian cancer cell. Con- 
sidering that the suppression effects on migra-
tion were observed consistently in 3 ovarian 
cancer cell lines (HO-8910PM, OVCAR3 and 
SKOV3), it is not likely that this inhibition was 
caused by artificial events. Additionally, ARL4C 
expression has no effect on growth of ovarian 
cancer cells, proposing that ARL4C may be not 
a typical tumor suppressor gene, i.e., it regu-
lates migration but not growth of cancer cells. 
Thus, the genomic variations on ARL4C may be 
evolutionally late events in tumor progression. 
Recently, Matsumoto et al reported that Wnt 
and growth factor signaling induces Arl4c 
expression [28]. The Wnt/β-catenin pathway is 
thought to be one of the major signaling path-
ways involved in epithelial-to-mesenchymal 
transition (EMT), a process occurred in the ini-
tiation of metastasis for cancer progression 
[29, 30]. The mechanism by which ARL4C regu-
lates cancer cell migration might lie in the 
crosstalk between ARL4C and EMT process, 
which warrants further studies in more cancer 
cell lines and tissue samples. 
Furthermore, our analysis of patient tumor 
samples provided additional evidence in sup-
port of our in vitro findings. ARL4C mRNA 
expression in tumor samples tended to be 
lower in patients with residual tumors or poor 
treatment response than in those without 
residual tumors or good treatment response. In 
addition, ARL4C mRNA expression was also 
positively associated with overall survival time. 
Patients with high or medium levels of expres-
sion had longer overall survival than those with 
low expression. These findings suggest that 
ARL4C may play a role in ovarian cancer pro-
gression and could be a candidate marker for 
ovarian cancer prognosis.
To date, no study has documented a direct link 
between ARL4C and cancer, but some microar-
ray data from Gene Expression Omnibus (GEO) 
(http://www.ncbi.nlm.nih.gov/geoprofiles? 
term= ARL4C% 20and%20(metastasis%20or% 
20progression)%20and%20cancer) 20% and 
20% cancer) seem to support our finding. 
Provenzani et al evaluated the gene expression 
profiles between SW480 and SW620 colon cell 
lines. SW620, established from a metastatic 
lymph node, is a subline of SW480. Similar to 
our results, their data also showed the expres-
sion of ARL4C mRNA being significantly lower in 
SW620 than in SW480 [31]. Genome-wide 
transcription analysis of  chemo-sensitive and 
chemo-resistant ovarian cancer cells in 
response to carboplatin treatment indicated 
that ARL4C was down-regulated in the chemo-
Table 4. Associations of ARL4C mRNA expression and patient survival from Italy1
Crude HRb 95% CI2 p-value Adjust HRd 95% CI p-value
Disease-Free Survival3
    Low ARL4C 1 1
    Medium and High ARL4C 0.85 0.55-1.31 0.464 0.82 0.53-1.28 0.387
Overall Survival4 
    Low ARL4C 1 1
    Medium and High ARL4C 0.61 0.40-0.93 0.021 0.59 0.39-0.91 0.017
1Hazard Ratios from Cox models were adjusted by grade, histology, stage and residual tumor. Significance level of p=0.05. 295% 
Wald confidence limits. 3Hazard ratio (HR) for replase with respect to negative expression of ARL4C. 4Hazard ratio (HR) for death 
with respect to negative expression of ARL4C. 5bold-italic value are statistically significant (p=0.05).
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resistant cells [32]. Additionally, to explore the 
function of DJ-1 in lung cancer, Clements et al 
examined its effect on global gene expression 
using Affymetrix GeneChip. After siRNA-mediat-
ed knockdown of DJ-1, ARL4C expression was 
significantly up-regulated, suggesting that AR- 
L4C may be negatively regulated by DJ-1 [33]. 
DJ-1 was initially described as a Parkinson’s 
disease-related gene [34] and then a putative 
oncogene which could transform mouse NIH- 
3T3 cells in cooperation with Ras [35]. Mo- 
reover, DJ-1 was proved to be a key suppressor 
of PTEN [36]. Recent studies reported that DJ-1 
was able to promote invasion and metastasis 
of pancreatic cancer cells by activating SRC/
ERK/uPA [37].
To our knowledge, this is the first study suggest-
ing that ARL4C may play an important role in 
ovarian cancer. Our understanding of ARL4C’s 
role in cancer is still quite limited. Much remains 
to be elucidated, including the relationship 
between DJ-1 and ARL4C in ovarian cancer and 
identification of downstream targets or path-
ways being involved in tumor cell migration and 
invasion. With a comprehensive understanding 
of ARL4C regulation and function, we may be 
able to explain how ARL4C is involved in ovari-
an cancer progression.
In summary, ARL4C was identified as a novel 
ovarian cancer-related gene by integrated mo- 
lecular and genomic technologies. ARL4C was 
down-related in metastatic ovarian cancer ce- 
lls. Its expression does not affect colony forma-
tion and cell proliferation, but negatively regu-
lates cell motility. In vitro experiments suggest 
that ARL4C suppresses ovarian cancer cell 
migration, and clinical study indicates that high 
ARL4C expression is associated with better 
overall survival of ovarian cancer patients. 
Tumor analysis also suggests that ARL4C may 
serve as a candidate marker for ovarian cancer 
prognosis. More studies are needed to further 
elucidate the molecular mechanisms by which 
ARL4C effects in ovarian cancer progression.
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